EBS - Emergent Biosolutions, Inc. -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Emergent Biosolutions, Inc.
Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics.
IPO Date: December 1, 2006
Sector: Healthcare
Industry: Biotech
Market Cap: $349.17M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.63 | 2.56%
Avg Daily Range (30 D): $0.22 | 3.42%
Avg Daily Range (90 D): $0.21 | 3.11%
Institutional Daily Volume
Avg Daily Volume: .56M
Avg Daily Volume (30 D): .95M
Avg Daily Volume (90 D): .87M
Trade Size
Avg Trade Size (Sh.): 107
Avg Trade Size (Sh.) (30 D): 88
Avg Trade Size (Sh.) (90 D): 79
Institutional Trades
Total Institutional Trades: 5,373
Avg Institutional Trade: $2.39M
Avg Institutional Trade (30 D): $1.15M
Avg Institutional Trade (90 D): $1.2M
Avg Institutional Trade Volume: .08M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $3.04M
Avg Closing Trade (30 D): $1.17M
Avg Closing Trade (90 D): $1.19M
Avg Closing Volume: 111.11K
 
News
Oct 6, 2026 @ 8:07 AM
Emergent Biosolutions (EBS) Soars 14.4%: Is Furthe...
Source: Zacks.Com
Sep 23, 2026 @ 12:46 AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: Pomerantz Llp
Sep 10, 2026 @ 12:30 AM
Intravenous Immunoglobulin Market Size Worth USD 3...
Source: Sns Insider
Sep 8, 2026 @ 9:56 PM
INVESTOR ALERT: Pomerantz Law Firm Investigates Cl...
Source: Pomerantz Llp
Feb 12, 2026 @ 11:00 PM
Emergent BioSolutions Receives U.S. FDA Approval o...
Source: Na
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-3.41 $-3.49 $.13
Diluted EPS $-3.47 $-3.49 $.07
Revenue $770.2M $234.3M $156.1M
Gross Profit $430.3M $137.2M $84.1M
Net Income / Loss $-176.8M $-180.2M $6.8M
Operating Income / Loss $-66M $-125.1M $10.5M
Cost of Revenue $339.9M $97.1M $72M
Net Cash Flow $-130.1M $-20.6M $-47.6M
PE Ratio